[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608549":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":42,"studyPopulation":35,"armGroups":43,"interventions":50,"overallOfficials":35,"centralContacts":56,"locations":64,"responsibleParty":287,"collaborators":35,"id":289,"slug":290,"hasResults":291,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":35,"eligibilityCriteria":295,"healthyVolunteers":291,"sex":296,"minAge":297,"maxAge":35,"enrollmentInfo":298,"targetDuration":35,"studyType":301,"phases":302,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":81,"whyStopped":35,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},{"fullName":5,"class":6},"Novartis","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":35},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants with clinical response based on one set of response criteria","Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival.","Day 85",[14,16,20,24,28,31],{"measure":15,"description":11,"timeFrame":12},"Number of participants with clinical response based on another set of response criteria",{"measure":17,"description":18,"timeFrame":19},"Response based on a biomarker level","To evaluate the efficacy of MAS825 in reducing clinical disease activity","Baseline, Day 85",{"measure":21,"description":22,"timeFrame":23},"Change in physician assessment based on laboratory features of MAS825","To assess the effect of MAS825 on macrophage activation syndrome","Baseline, 15 months",{"measure":25,"description":26,"timeFrame":27},"Change from baseline in Glucocorticoid (GC) dose","To evaluate the efficacy of MAS825 as a glucocorticoid-sparing agent","Baseline, Day 85, Month 6, Month 12",{"measure":29,"description":30,"timeFrame":19},"Change from baseline in patient\u002Fparent assessment of physical function as assessed by Quality of Life instrument","To evaluate the efficacy of MAS825 in improving participant's quality of life",{"measure":32,"description":33,"timeFrame":34},"Clinically inactive disease whilst on non-treatment dose corticosteroid at any time during the study","The number of participants with inactive disease will be assessed. Disease activity will be evaluated by the investigator based on physical examination and laboratory parameters.\n\nInactive disease is defined according to protocol-specific criteria, which include clinical signs, laboratory values, and physician assessment.","15 months",null,{"allocation":37,"interventionModel":38,"interventionModelDescription":35,"primaryPurpose":39,"observationalModel":35,"timePerspective":35,"maskingInfo":40},"NA","SINGLE_GROUP","TREATMENT",{"masking":41,"maskingDescription":35,"whoMasked":35},"NONE","This is a multicenter, open-label, single-arm study to assess clinical efficacy, safety and tolerability of MAS825 in participants (both pediatric and adult) with Still's disease who have had inadequate response to IL-1 and\u002For IL-6 or other available therapies. Participants with associated lung disease and\u002For macrophage activation syndrome may also be included.\n\nThis study has three periods (Screening, Treatment Period 1, and Treatment Period 2) and a total duration of approximately 16 months.",[44],{"label":45,"type":46,"description":47,"interventionNames":48},"MAS825","EXPERIMENTAL","Experimental drug",[49],"Drug: MAS825",[51],{"type":52,"name":45,"description":47,"armGroupLabels":53,"otherNames":54},"DRUG",[45],[55],"Arumakimig",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":35,"email":61},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":58,"role":59,"phone":63,"phoneExt":35,"email":35},"+41613241111",[65,79,98,115,128,133,143,151,159,167,175,180,191,199,207,218,227,236,246,252,260,268,278],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":35},"Cincinnati Childrens Hospital","ACTIVE_NOT_RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-84.51439,39.12711,{"lat":77,"lon":76},{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":71,"countryCode":72,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Legacy Emanuel Research Hosp Portland","RECRUITING","Portland","Oregon","97232",{"type":74,"coordinates":86},[87,88],-122.67621,45.52345,{"lat":88,"lon":87},[91,95],{"name":92,"role":59,"phone":93,"phoneExt":35,"email":94},"Brenna Bogle","+1 503 413 5447","bbogle@lhs.org",{"name":96,"role":97,"phone":35,"phoneExt":35,"email":35},"Daniel Joseph Kingsbury","PRINCIPAL_INVESTIGATOR",{"facility":99,"status":81,"city":100,"state":101,"zip":102,"country":71,"countryCode":72,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"University of Utah","Salt Lake City","Utah","84113",{"type":74,"coordinates":104},[105,106],-111.89105,40.76078,{"lat":106,"lon":105},[109,113],{"name":110,"role":59,"phone":111,"phoneExt":35,"email":112},"Tressie Rollins","+1 415 515 8212","tressie.rollins@hsc.utah.edu",{"name":114,"role":97,"phone":35,"phoneExt":35,"email":35},"Aimee Ogden Hersh",{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":121,"countryCode":122,"cosmosGeoPoint":123,"geoPoint":127,"contacts":35},"Novartis Investigative Site","WITHDRAWN","Montreal","Quebec","H3T 1C5","Canada","CA",{"type":74,"coordinates":124},[125,126],-73.58781,45.50884,{"lat":126,"lon":125},{"facility":116,"status":117,"city":118,"state":119,"zip":129,"country":121,"countryCode":122,"cosmosGeoPoint":130,"geoPoint":132,"contacts":35},"H4A 3J1",{"type":74,"coordinates":131},[125,126],{"lat":126,"lon":125},{"facility":116,"status":81,"city":134,"state":35,"zip":135,"country":136,"countryCode":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":35},"Bordeaux","33076","France","FR",{"type":74,"coordinates":139},[140,141],-0.58046,44.84124,{"lat":141,"lon":140},{"facility":116,"status":81,"city":144,"state":35,"zip":145,"country":136,"countryCode":137,"cosmosGeoPoint":146,"geoPoint":150,"contacts":35},"Bron","69677",{"type":74,"coordinates":147},[148,149],4.91303,45.73865,{"lat":149,"lon":148},{"facility":116,"status":81,"city":152,"state":35,"zip":153,"country":136,"countryCode":137,"cosmosGeoPoint":154,"geoPoint":158,"contacts":35},"Le Kremlin-Bicêtre","94275",{"type":74,"coordinates":155},[156,157],2.36073,48.81471,{"lat":157,"lon":156},{"facility":116,"status":81,"city":160,"state":35,"zip":161,"country":136,"countryCode":137,"cosmosGeoPoint":162,"geoPoint":166,"contacts":35},"Lille","59037",{"type":74,"coordinates":163},[164,165],3.05512,50.63391,{"lat":165,"lon":164},{"facility":116,"status":81,"city":168,"state":35,"zip":169,"country":136,"countryCode":137,"cosmosGeoPoint":170,"geoPoint":174,"contacts":35},"Paris","75015",{"type":74,"coordinates":171},[172,173],2.3488,48.85341,{"lat":173,"lon":172},{"facility":116,"status":81,"city":168,"state":35,"zip":176,"country":136,"countryCode":137,"cosmosGeoPoint":177,"geoPoint":179,"contacts":35},"75970",{"type":74,"coordinates":178},[172,173],{"lat":173,"lon":172},{"facility":116,"status":81,"city":181,"state":182,"zip":183,"country":184,"countryCode":185,"cosmosGeoPoint":186,"geoPoint":190,"contacts":35},"Sankt Augustin","North Rhine-Westphalia","53757","Germany","DE",{"type":74,"coordinates":187},[188,189],7.197,50.77538,{"lat":189,"lon":188},{"facility":116,"status":81,"city":192,"state":35,"zip":193,"country":184,"countryCode":185,"cosmosGeoPoint":194,"geoPoint":198,"contacts":35},"Heidelberg","69120",{"type":74,"coordinates":195},[196,197],8.69079,49.40768,{"lat":197,"lon":196},{"facility":116,"status":81,"city":200,"state":35,"zip":201,"country":184,"countryCode":185,"cosmosGeoPoint":202,"geoPoint":206,"contacts":35},"Münster","48149",{"type":74,"coordinates":203},[204,205],7.62571,51.96236,{"lat":205,"lon":204},{"facility":116,"status":81,"city":208,"state":209,"zip":210,"country":211,"countryCode":212,"cosmosGeoPoint":213,"geoPoint":217,"contacts":35},"Florence","FI","50139","Italy","IT",{"type":74,"coordinates":214},[215,216],11.24626,43.77925,{"lat":216,"lon":215},{"facility":116,"status":81,"city":219,"state":220,"zip":221,"country":211,"countryCode":212,"cosmosGeoPoint":222,"geoPoint":226,"contacts":35},"Genova","GE","16147",{"type":74,"coordinates":223},[224,225],11.87211,45.21604,{"lat":225,"lon":224},{"facility":116,"status":81,"city":228,"state":229,"zip":230,"country":211,"countryCode":212,"cosmosGeoPoint":231,"geoPoint":235,"contacts":35},"Roma","RM","00165",{"type":74,"coordinates":232},[233,234],11.10642,44.99364,{"lat":234,"lon":233},{"facility":116,"status":67,"city":237,"state":35,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":35},"Utrecht","3584 CX","Netherlands","NL",{"type":74,"coordinates":242},[243,244],5.12222,52.09083,{"lat":244,"lon":243},{"facility":116,"status":81,"city":247,"state":248,"zip":249,"country":250,"countryCode":251,"cosmosGeoPoint":35,"geoPoint":35,"contacts":35},"Esplugues","Barcelona","08950","Spain","ES",{"facility":116,"status":81,"city":253,"state":35,"zip":254,"country":250,"countryCode":251,"cosmosGeoPoint":255,"geoPoint":259,"contacts":35},"Madrid","28046",{"type":74,"coordinates":256},[257,258],-3.70256,40.4165,{"lat":258,"lon":257},{"facility":116,"status":81,"city":261,"state":35,"zip":262,"country":250,"countryCode":251,"cosmosGeoPoint":263,"geoPoint":267,"contacts":35},"Valencia","46026",{"type":74,"coordinates":264},[265,266],-0.37966,39.47391,{"lat":266,"lon":265},{"facility":116,"status":81,"city":269,"state":270,"zip":271,"country":272,"countryCode":35,"cosmosGeoPoint":273,"geoPoint":277,"contacts":35},"Istanbul","Fatih","34098","Turkey (Türkiye)",{"type":74,"coordinates":274},[275,276],28.94966,41.01384,{"lat":276,"lon":275},{"facility":116,"status":81,"city":279,"state":280,"zip":281,"country":272,"countryCode":35,"cosmosGeoPoint":282,"geoPoint":286,"contacts":35},"Ankara","Sihhiye-Altindag","06230",{"type":74,"coordinates":283},[284,285],32.85427,39.91987,{"lat":285,"lon":284},{"type":288,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100608549","phase-2-a-phase-ii-trial-to-evaluate-the-clinical-efficacy-safety-and-tolerability-of-mas825-in-pediatric-and-adult-participants-with-stills-disease-100608549",false,"NCT07203001","A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease","An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease","Inclusion Criteria:\n\n* Age ≥ 1 with a diagnosis of Still's Disease\n* Active diseases defined as:\n* CRP or ferritin levels greater than ULN, and any of:\n\n  * Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or\n  * Rash attributed to Still's Disease activity or\n  * Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or\n  * Serositis or\n  * Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator\n* Intolerance or inadequate response to available biologic therapy\n\nExclusion Criteria:\n\n* Patients out of weight range\n* Ongoing or previous treatment with immunomodulatory drugs\n\n  * A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study\n* Glucocorticoid dose exceeding a set limit\n* Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy\n\n  * Still's disease patients with evidence of macrophage activation syndrome are permitted in the study\n  * Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study\n* History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and\u002For symptoms and signs of clinically significant active bacterial, fungal or viral infections\n* Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose\n* History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases\n* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients\n* Pregnant or breastfeeding women\n* Women of child-bearing potential who do not agree to comply with required contraceptive use\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","1 Year",{"count":299,"type":300},30,"ESTIMATED","INTERVENTIONAL",[303],"PHASE2","The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease",[306],"Still´s Disease",[308,309,310,311,312,313,314,315,45,316],"Still´s disease","pediatric","adult","sJIA","AOSD","Systemic Juvenile Idiopathic Arthritis","Adult Onset Still s disease","rheumatology","arumakimig","2026-09-07",{"date":319,"type":320},"2026-09-09","ACTUAL",{"date":322,"type":320},"2025-11-03",{"date":324,"type":300},"2028-05-17",{"name":58,"class":6},23]